New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:45 EDTAGEN, GSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Agenus (AGEN) announced that GlaxoSmithKline’s (GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer, or NSCLC, patients, which contains Agenus’QS-21 Stimulon adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. The Independent Data Monitoring Committee, or IDMC, indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic. GSK is continuing another Phase 3 clinical trial to evaluate whether a gene signature can identify a sub-population of melanoma patients that would benefit from the same investigational MAGE-A3 cancer immunotherapeutic.
News For AGEN;GSK From The Last 14 Days
Check below for free stories on AGEN;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2014
15:38 EDTGSKGlaxoSmithKline Tanzeum available in U.S. pharmacies
Subscribe for More Information
07:40 EDTGSKCourt date set for Glaxo investigators arrested in China, WSJ says
Two investigators who were hired by GlaxoSmithKline last year to look into a sex video taken of the drug company's top China executive, and who were subsequently placed in custody by Chinese authorities on charges of illegally purchasing personal information about Chinese nationals, will stand trial August 8, reported The Wall Street Journal. Reference Link
July 28, 2014
10:02 EDTGSKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AcelRx (ACRX) downgraded to Hold from Buy at Canaccord... Anglo American (AAUKY) downgraded to Neutral from Buy at UBS... Aon plc (AON) downgraded to Hold from Buy at Sandler ONeill... Cabot Oil & Gas (COG) downgraded at Oppenheimer... Cisco (CSCO) downgraded to Sector Perform from Outperform at Pacific Crest... Coeur Mining (CDE) downgraded to Market Perform from Outperform at Raymond James... DSW (DSW) downgraded at Sterne Agee... DuPont Fabros (DFT) downgraded to Neutral from Buy at Citigroup... El Paso Electric (EE) downgraded to Hold from Buy at Jefferies... Enphase Energy (ENPH) downgraded to Hold from Buy at Deutsche Bank... GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill... Horizon Technology (HRZN) downgraded to Hold from Buy at Wunderlich... Lear (LEA) downgraded to Hold from Buy at Deutsche Bank... Life Time Fitness (LTM) downgraded at Wedbush... Monster Beverage (MNST) downgraded to Neutral from Buy at UBS... NRG Energy (NRG) downgraded to Buy from Conviction Buy at Goldman... PG&E (PCG) downgraded to Sell from Neutral at Goldman... Pfizer (PFE) downgraded at BMO Capital... Post Properties (PPS) downgraded to Neutral from Buy at Citigroup... Publicis (PUBGY) downgraded to Sell from Neutral at Citigroup... Selmer Scientific (SMLR) downgraded to Hold from Buy at Aegis... TransCanada (TRP) downgraded to Neutral from Outperform at Credit Suisse... Travelers (TRV) downgraded to Hold from Buy at Sandler O'Neill... Zurich Insurance (ZURVY) downgraded to Underperform from Market Perform at Bernstein.
08:09 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at BofA/Merrill
06:22 EDTGSKGlaxoSmithKline could eventually spin off consumer healthcare business, FT says
GlaxoSmithKline CEO Andrew Witty is considering the possibility of the company being broken up in the future, suggesting that the consumer healthcare business could be spun off if a time comes when it is more valuable as an independent company, the Financial Times reports. Witty says there are no such plans in the near term. Reference Link
July 24, 2014
13:29 EDTGSKGlaxoSmithKline facing bribery allegations in Syria, Reuters says
Subscribe for More Information
12:41 EDTGSKGlaxoSmithKline reports FDA approves Flonase for OTC sales in U.S.
Subscribe for More Information
11:45 EDTGSKGlaxoSmithKline downgraded to Sell from Neutral at UBS
Subscribe for More Information
07:09 EDTAGENAgenus reports Q2 EPS (12c), consensus (17c)
Subscribe for More Information
06:13 EDTGSK, AGENGlaxoSmithKline's malaria vaccine candidate accepted for EU regulatory review
Subscribe for More Information
July 23, 2014
09:33 EDTGSKGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
09:17 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
07:19 EDTGSKGenmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information
07:12 EDTGSKGlaxoSmithKline lowers 2014 core EPS outlook to 'similar' to 2013
GSK now expects 2014 core EPS to be "broadly similar" to 2013 versus previous expectations of 4%-8% growth. It added, "Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial."
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
July 22, 2014
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
July 21, 2014
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 17, 2014
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use